Archive
Every story, newest first.
Monday, November 2, 2026
Infrastructure
TotalEnergies has signed agreements to acquire a 30 percent operated interest in the Lang Lebah and B14 gas fields offshore Sarawak, an integrated development expected to unlock more than 6.5 trillion cubic feet of gas for the Malaysia LNG plant.
Infrastructure
Britain's National Housing Bank anchored a single-family rental fund at 200 million pounds of capacity, South African ministers counted 548 billion rand of special economic zone pledges, and Nigeria's OPay withdrew its planned $304 million US listing.
Infrastructure
Google will spend $160 million on an off-river storage reservoir and water treatment plant on Malaysia's Linggi River, built by Gamuda Berhad and owned by the Negeri Sembilan state, to support its planned Port Dickson data centre campus.
Infrastructure
South Eastern Coalfields, Coal India's second-largest producing subsidiary, has filed a draft prospectus for an initial public offering made up entirely of an offer for sale of up to 668.1 million shares by its parent, with no new money for the company.
Infrastructure
BP has completed the sale of a 65 percent stake in its Castrol lubricants business to Stonepeak, receiving $6 billion in after-tax proceeds that it will use to reduce debt, and retaining 35 percent in a new joint venture.
Infrastructure
Apollo Global Management has launched the European Credit Company, a private credit platform with more than 10 billion euros ($11.2 billion) of lending capacity, backed by the Abu Dhabi Investment Council, Athora, Norinchukin Bank, Standard Chartered and Aranda Principal Strategies.
Infrastructure
Afreximbank and the African Petroleum Producers' Organisation formally established the Africa Energy Bank at its inaugural general meeting in Abuja on October 31, with $5 billion of authorised capital and Helmy Ghazi appointed as its first president.
Life Sciences
The FDA approved Pfizers Talzenna with enzalutamide on October 26 for earlier metastatic prostate cancer with HRR gene mutations, after TALAPRO-3 cut the risk of progression or death by 52 percent, with median progression free survival not reached against 45.8 months.
Life Sciences
BioMarin will pay 70 million dollars upfront, plus up to 405 million dollars in milestones and tiered royalties, for worldwide rights outside South Korea to HM15421/GC1134A, a Phase 1/2 long acting enzyme replacement therapy for Fabry disease.
Life Sciences
Smaller life sciences items on November 2 include a routine Haleon buyback purchase of 4,492,636 shares, a February 28, 2027 FDA goal date for Palvellas QTORIN gel, and the start of Viatris tender offer for Pacira at 36.50 dollars a share.